An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study

Authors: Michael R. Savona, Olatoyosi Odenike, Philip C. Amrein, David P. Steensma, Amy E. DeZern, Laura C. Michaelis, Stefan Faderl, Wael A. Harb, Hagop M. Kantarjian, James N. Lowder, Aram Oganesian, Mohammad Azab, Guillermo Garcia‐Manero - The Lancet 2019 cited by 120